Cover Image

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study...

Full description

Saved in:
Bibliographic Details
Main Authors: Corthals, Sophie L. (Author) , Kuiper, Rowan (Author) , Johnson, David C. (Author) , Sonneveld, Pieter (Author) , Hajek, Roman (Author) , Holt, Bronno van der (Author) , Magrangeas, Florence (Author) , Goldschmidt, Hartmut (Author) , Morgan, Gareth J. (Author) , Avet-Loiseau, Hervé (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: Haematologica, the hematology journal
Year: 2011, Volume: 96, Issue: 11, Pages: 1728-1732
ISSN:1592-8721
DOI:10.3324/haematol.2011.041434
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3324/haematol.2011.041434
Verlag, kostenfrei, Volltext: https://haematologica.org/article/view/6136
Get full text
Author Notes:Sophie L. Corthals, Rowan Kuiper, David C. Johnson, Pieter Sonneveld, Roman Hajek, Bronno van der Holt, Florence Magrangeas, Hartmut Goldschmidt, Gareth J. Morgan, and Hervé Avet-Loiseau
Description
Summary:Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study was performed using a discovery set (IFM 2005-01; n=238) and a validation set (HOVON65/GMMG-HD4 and a Czech dataset; n=231). After multiplicity correction, none of the 2,149 single nucleotide polymorphisms tested revealed any significant association with bortezomib induced peripheral neuropathy. However, 56 single nucleotide polymorphisms demonstrated an association with bortezomib induced peripheral neuropathy with pointwise, uncorrected significance. Pathway analysis of these polymorphisms demonstrated involvement of neurological disease (FDR
Item Description:Gesehen am 13.04.2022
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.2011.041434

Similar Items